Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Cervical Cancer

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 223 articles:
HTML format

Single Articles

    January 2024
    Improving prediction of cervical cancer using KNN imputer and multi-model ensemble learning.
    PLoS One. 2024;19:e0295632.
    PubMed     Abstract available

    Novel ensemble learning approach with SVM-imputed ADASYN features for enhanced cervical cancer prediction.
    PLoS One. 2024;19:e0296107.
    PubMed     Abstract available

  3. YU C, Wu X, Zhang S, Zhang L, et al
    Prognostic model for survival in patients with neuroendocrine carcinomas of the cervix: SEER database analysis and a single-center retrospective study.
    PLoS One. 2024;19:e0296446.
    PubMed     Abstract available

  4. GUILLAUME D, Waheed DE, Schleiff M, Muralidharan KK, et al
    Global perspectives of determinants influencing HPV vaccine introduction and scale-up in low- and middle-income countries.
    PLoS One. 2024;19:e0291990.
    PubMed     Abstract available

  5. SARMIENTO-MEDINA MI, de Amaya MP, Villamizar-Gomez L, Gonzalez-Coba AC, et al
    High-risk HPV prevalence and vaccination coverage among Indigenous women in the Colombian Amazon: Implications for cervical cancer prevention. Cross-sectional study.
    PLoS One. 2024;19:e0297579.
    PubMed     Abstract available

  6. KANG SW, Kang OJ, Lee JY, Kim H, et al
    Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer.
    PLoS One. 2024;19:e0298815.
    PubMed     Abstract available

  7. MANGENAH C, Sibanda EL, Maringwa G, Sithole J, et al
    Provider and female client economic costs of integrated sexual and reproductive health and HIV services in Zimbabwe.
    PLoS One. 2024;19:e0291082.
    PubMed     Abstract available

    Correction: Novel ensemble learning approach with SVM-imputed ADASYN features for enhanced cervical cancer prediction.
    PLoS One. 2024;19:e0298980.
    PubMed     Abstract available

  9. VARON ML, Geng Y, Fellman BM, Troisi C, et al
    Interventions to increase follow-up of abnormal cervical cancer screening results: A systematic literature review and meta-analysis.
    PLoS One. 2024;19:e0291931.
    PubMed     Abstract available

  10. YAO B, Peng J, Song W, Yang L, et al
    Real-world effectiveness of cytology and HPV-based screening strategy in cervical cancer screening: A cross-sectional population-based study in Chengdu, China.
    PLoS One. 2024;19:e0299651.
    PubMed     Abstract available

  11. SUN J, Frick KD, Liang H, Chow CM, et al
    Examining cancer screening disparities by race/ethnicity and insurance groups: A comparison of 2008 and 2018 National Health Interview Survey (NHIS) data in the United States.
    PLoS One. 2024;19:e0290105.
    PubMed     Abstract available

  12. ZHANG J, Yuan J, Zhang D, Yang Y, et al
    Short video platforms as sources of health information about cervical cancer: A content and quality analysis.
    PLoS One. 2024;19:e0300180.
    PubMed     Abstract available

  13. CAROZZI FM, Royder Yanez R, Paganini I, Sani C, et al
    Cervical cancer prevention: Feasibility of self-sampling and HPV testing in rural and urban areas of Bolivia: An observational study.
    PLoS One. 2024;19:e0292605.
    PubMed     Abstract available

  14. LIU Z, Fan T, Mo X, Kan J, et al
    Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study.
    PLoS One. 2024;19:e0298271.
    PubMed     Abstract available

  15. LIN Y, Long Y, He J, Yi Q, et al
    The residual rate of HPV and the recurrence rate of CIN after LEEP with negative margins: A meta-analysis.
    PLoS One. 2024;19:e0298520.
    PubMed     Abstract available

  16. OOMMEN AM, Isaac R, Paul B, Weller D, et al
    Strategies for primary HPV test-based cervical cancer screening programme in resource-limited settings in India: Results from a quasi-experimental pragmatic implementation trial.
    PLoS One. 2024;19:e0301385.
    PubMed     Abstract available

  17. LEMLEM SB, Gary RA, Yeager KA, Sisay MM, et al
    Psychometric properties of a modified health belief model for cervical cancer and visual inspection with acetic acid among healthcare professionals in Ethiopia.
    PLoS One. 2024;19:e0295905.
    PubMed     Abstract available

  18. KHUMALO PG, Carey M, Mackenzie L, Sanson-Fisher R, et al
    Cervical cancer screening knowledge and associated factors among Eswatini women: A cross-sectional study.
    PLoS One. 2024;19:e0300763.
    PubMed     Abstract available

  19. DUA R, Bhardwaj T, Ahmad I, Somvanshi P, et al
    Investigating the potential of Juglans regia phytoconstituents for the treatment of cervical cancer utilizing network biology and molecular docking approach.
    PLoS One. 2024;19:e0287864.
    PubMed     Abstract available

  20. ZEBER-LUBECKA N, Kulecka M, Dabrowska M, Baginska-Drabiuk K, et al
    Cervical microbiota dysbiosis associated with high-risk Human Papillomavirus infection.
    PLoS One. 2024;19:e0302270.
    PubMed     Abstract available

  21. XU F, Carlson SA, Greenlund KJ
    Understanding primary care providers' attitudes towards preventive screenings to patients with inflammatory bowel disease.
    PLoS One. 2024;19:e0299890.
    PubMed     Abstract available

  22. MOSHI JM, Ummelen M, Smedts F, Ramaekers FCS, et al
    Inhibition of cytosine 5-hydroxymethylation during progression of cancer precursor lesions in the uterine cervix.
    PLoS One. 2024;19:e0297008.
    PubMed     Abstract available

  23. TIRKASO BH, Bayisa TH, Desta TW
    Histopathologic patterns and factors associated with cervical lesions at Jimma Medical Center, Jimma, Southwest Ethiopia: A two-year cross-sectional study.
    PLoS One. 2024;19:e0301559.
    PubMed     Abstract available

  24. WANG QL, Gong C, Meng XY, Fu M, et al
    TPP1 is associated with risk of advanced precursors and cervical cancer survival.
    PLoS One. 2024;19:e0298118.
    PubMed     Abstract available

  25. SHIMELS T, Gashawbeza B, Fenta TG
    Validation of the Amharic version of perceived access to healthcare services for patients with cervical cancer in Ethiopia: A second-order confirmatory factor analysis.
    PLoS One. 2024;19:e0300815.
    PubMed     Abstract available

  26. ILIKA CP, Eleje GU, Chiemeka ME, Ilika FN, et al
    Effects of speculum lubrication on cervical smears for cervical cancer screening: A double blind randomized clinical trial.
    PLoS One. 2024;19:e0292207.
    PubMed     Abstract available

  27. BROSHKEVITCH CJ, Barnabas RV, Liu G, Palanee-Phillips T, et al
    Enhanced cervical cancer and HIV interventions reduce the disproportionate burden of cervical cancer cases among women living with HIV: A modeling analysis.
    PLoS One. 2024;19:e0301997.
    PubMed     Abstract available

  28. HUSSEIN K, Kokwaro G, Wafula F, Kassie GM, et al
    Assessing the influence of the health system on access to cervical cancer prevention, screening, and treatment services at public health centers in Addis Ababa, Ethiopia.
    PLoS One. 2024;19:e0300152.
    PubMed     Abstract available

  29. AGYARE GYANE F, Modey E, Maya E, Bonney EY, et al
    Prevalence and risk factors associated with high-risk human papillomavirus infection among women living with HIV (WLWH) at a tertiary health facility in Accra, Ghana.
    PLoS One. 2024;19:e0303535.
    PubMed     Abstract available

    January 2023
  30. BUNTING SR, Morris S, Chael J, Feinstein BA, et al
    Knowledge of human papillomavirus vaccination: A multi-institution, cross-sectional study of allopathic and osteopathic medical students.
    PLoS One. 2023;18:e0280287.
    PubMed     Abstract available

  31. ABERA GB, Yebyo HG, Hailekiros H, Niguse S, et al
    Epidemiology of pre-cancerous cervical lesion and risk factors among adult women in Tigray, Ethiopia.
    PLoS One. 2023;18:e0280191.
    PubMed     Abstract available

  32. NARTEY Y, Amo-Antwi K, Hill PC, Dassah ET, et al
    Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.
    PLoS One. 2023;18:e0280437.
    PubMed     Abstract available

  33. DE FOUW M, Stroeken Y, Niwagaba B, Musheshe M, et al
    Involving men in cervical cancer prevention; a qualitative enquiry into male perspectives on screening and HPV vaccination in Mid-Western Uganda.
    PLoS One. 2023;18:e0280052.
    PubMed     Abstract available

  34. OKUNADE KS, Badmos KB, Okoro AC, Ademuyiwa IY, et al
    Comparative Assessment of p16/Ki-67 Dual Staining Technology for cervical cancer screening in women living with HIV (COMPASS-DUST)-Study protocol.
    PLoS One. 2023;18:e0278077.
    PubMed     Abstract available

  35. VILLAVICENCIO A, Kelsey G, Nogueira NF, Zukerberg J, et al
    Knowledge, attitudes, and practices towards HPV vaccination among reproductive age women in a HIV hotspot in the US.
    PLoS One. 2023;18:e0275141.
    PubMed     Abstract available

  36. WONGJAMPA W, Nakahara T, Tanaka K, Yugawa T, et al
    An in vitro carcinogenesis model for cervical cancer harboring episomal form of HPV16.
    PLoS One. 2023;18:e0281069.
    PubMed     Abstract available

  37. FLEIDER LA, de Los Angeles Tinnirello M, Gomez Cherey F, Garcia MG, et al
    High sensitivity and specificity rates of cobas(R) HPV test as a primary screening test for cervical intraepithelial lesions in a real-world setting.
    PLoS One. 2023;18:e0279728.
    PubMed     Abstract available

  38. RODRIGUEZ NM, Brennan LP, Claure L, Balian LN, et al
    Leveraging COVID-era innovation for cervical cancer screening: Clinician awareness and attitudes toward self-sampling and rapid testing for HPV detection.
    PLoS One. 2023;18:e0282853.
    PubMed     Abstract available

  39. YAN L, Xiao X, He L, Shi L, et al
    Efficacy of optical coherence tomography in the triage of women with minor abnormal cervical cytology before colposcopy.
    PLoS One. 2023;18:e0282833.
    PubMed     Abstract available

  40. CHOI J, Markham C, Tami-Maury I, Kim S, et al
    Maternal perceptions of vaccinating boys against human papillomavirus (HPV) in Seoul, South Korea: A descriptive exploratory qualitative study.
    PLoS One. 2023;18:e0282811.
    PubMed     Abstract available

  41. GIBSON-HELM M, Slater T, MacDonald EJ, Stevenson K, et al
    Te Ara Waiora-Implementing human papillomavirus (HPV) primary testing to prevent cervical cancer in Aotearoa New Zealand: A protocol for a non-inferiority trial.
    PLoS One. 2023;18:e0280643.
    PubMed     Abstract available

  42. SMITH JS, Vaz OM, Gaber CE, Des Marais AC, et al
    Recruitment strategies and HPV self-collection return rates for under-screened women for cervical cancer prevention.
    PLoS One. 2023;18:e0280638.
    PubMed     Abstract available

  43. TAKADA A, Yokota H, Nemoto MW, Horikoshi T, et al
    Prognosis prediction of uterine cervical cancer using changes in the histogram and texture features of apparent diffusion coefficient during definitive chemoradiotherapy.
    PLoS One. 2023;18:e0282710.
    PubMed     Abstract available

  44. PAKEN J, Govender CD, Pillay M, Feyasa M, et al
    Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.
    PLoS One. 2023;18:e0283639.
    PubMed     Abstract available

  45. LIVESEY M, Rossouw SC, Blignaut R, Christoffels A, et al
    Transforming RNA-Seq gene expression to track cancer progression in the multi-stage early to advanced-stage cancer development.
    PLoS One. 2023;18:e0284458.
    PubMed     Abstract available

  46. Expression of Concern: Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis.
    PLoS One. 2023;18:e0285579.

  47. HOLOPAINEN E, Lahtinen O, Kononen M, Anttila M, et al
    Greater increases in intratumoral apparent diffusion coefficients after chemoradiotherapy predict better overall survival of patients with cervical cancer.
    PLoS One. 2023;18:e0285786.
    PubMed     Abstract available

  48. OKAFOR IP, Kukoyi FO, Kanma-Okafor OJ, Izuka MO, et al
    Male involvement in female partners' screening for breast and cervical cancers in Southwest Nigeria.
    PLoS One. 2023;18:e0284141.
    PubMed     Abstract available

  49. MITI S, Shato T, Asante C, Baumann A, et al
    Leveraging health infrastructure to optimize HPV vaccination for adolescents in Zambia: Protocol for an implementation study.
    PLoS One. 2023;18:e0285031.
    PubMed     Abstract available

  50. KHOMPHAIBOONKIJ U, Sreamsukcharoenchai N, Pitakkarnkul S, Rittiluechai K, et al
    Knowledge of Thai women in cervical cancer etiology and screening.
    PLoS One. 2023;18:e0286011.
    PubMed     Abstract available

  51. KURITA Y, Meguro S, Tsuyama N, Kosugi I, et al
    Accurate deep learning model using semi-supervised learning and Noisy Student for cervical cancer screening in low magnification images.
    PLoS One. 2023;18:e0285996.
    PubMed     Abstract available

  52. PANERU B, Karmacharya A, Bharati A, Makaju S, et al
    Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal.
    PLoS One. 2023;18:e0285771.
    PubMed     Abstract available

  53. JEMAL Z, Chea N, Hasen H, Tesfaye T, et al
    Cervical cancer screening utilization and associated factors among female health workers in public health facilities of Hossana town, southern Ethiopia: A mixed method approach.
    PLoS One. 2023;18:e0286262.
    PubMed     Abstract available

  54. MWENDA V, Bor JP, Nyangasi M, Njeru J, et al
    Integrating human papillomavirus testing as a point-of care service using GeneXpert platforms: Findings and lessons from a Kenyan pilot study (2019-2020).
    PLoS One. 2023;18:e0286202.
    PubMed     Abstract available

  55. FUJITA M, Nagashima K, Shimazu M, Suzuki M, et al
    Acceptability of self-sampling human papillomavirus test for cervical cancer screening in Japan: A questionnaire survey in the ACCESS trial.
    PLoS One. 2023;18:e0286909.
    PubMed     Abstract available

  56. ALAM Z, Cairns JM, Scott M, Dean JA, et al
    Interventions to increase cervical screening uptake among immigrant women: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0281976.
    PubMed     Abstract available

  57. VAINER G, Huang L, Emancipator K, Nuti S, et al
    Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    PLoS One. 2023;18:e0285764.
    PubMed     Abstract available

  58. JONSDOTTIR B, Wikman A, Sundstrom Poromaa I, Stalberg K, et al
    Advanced gynecological cancer: Quality of life one year after diagnosis.
    PLoS One. 2023;18:e0287562.
    PubMed     Abstract available

  59. STRBAC M, Vukovic V, Pustahija T, Nikolic N, et al
    Motives and attitudes of parents toward HPV vaccination: Results from the initial period of HPV vaccine rollout in Serbia.
    PLoS One. 2023;18:e0287295.
    PubMed     Abstract available

  60. WULANDARI D, Meidyandra RW, Andrijono
    Genotype profiles of high-risk human papillomavirus in women of reproductive age: A community-based study.
    PLoS One. 2023;18:e0287399.
    PubMed     Abstract available

  61. MAHAJAN H, Reddy N, Devi NGM, Poli UR, et al
    Projected cancer burden, challenges, and barriers to cancer prevention and control activities in the state of Telangana.
    PLoS One. 2023;18:e0278357.
    PubMed     Abstract available

  62. FAZLOLLAHPOUR-NAGHIBI A, Bagheri K, Almukhtar M, Taha SR, et al
    Trichomonas vaginalis infection and risk of cervical neoplasia: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0288443.
    PubMed     Abstract available

  63. BAS S, Sijben J, Bischoff EWMA, Bekkers RLM, et al
    Acceptability of risk-based triage in cervical cancer screening: A focus group study.
    PLoS One. 2023;18:e0289647.
    PubMed     Abstract available

  64. CONTRERAS NE, Roldan JS, Castillo DS
    Novel competitive enzyme-linked immunosorbent assay for the detection of the high-risk Human Papillomavirus 18 E6 oncoprotein.
    PLoS One. 2023;18:e0290088.
    PubMed     Abstract available

  65. CHONA EZ, Msengi EA, Gosse RA, Ambikile JS, et al
    The lived experiences and caring needs of women diagnosed with cervical cancer: A qualitative study in Dar es Salaam, Tanzania.
    PLoS One. 2023;18:e0289925.
    PubMed     Abstract available

  66. OKYERE ASANTE PG, Owusu AY, Oppong JR, Amegah KE, et al
    The psychosocial burden of women seeking treatment for breast and cervical cancers in Ghana's major cancer hospitals.
    PLoS One. 2023;18:e0289055.
    PubMed     Abstract available

  67. GONG M, Shen F, Li Y, Ming L, et al
    MLK4 as an immune marker and its correlation with immune infiltration in Cervical squamous cell carcinoma and endocervical adenocarcinoma(CESC).
    PLoS One. 2023;18:e0290462.
    PubMed     Abstract available

  68. URQUHART G, Maclennan SJ, Guntupalli AM
    Is there an association between intimate partner violence and the prevalence of cervical cancer screening in Jordan?
    PLoS One. 2023;18:e0290678.
    PubMed     Abstract available

  69. SUNDARA RAJAN R S, Thomas J, Francis D, Daniel EC, et al
    Effective gene delivery using size dependant nano core-shell in human cervical cancer cell lines by magnetofection.
    PLoS One. 2023;18:e0289731.
    PubMed     Abstract available

  70. ODEH HI, Al-Badi SR, Karima B, Saeed TA, et al
    Exploring the prevalence of Human Papillomavirus (HPV) genotypes in PAP smear samples of women in northern region of United Arab Emirates (UAE): HPV Direct Flow CHIP system-based pilot study.
    PLoS One. 2023;18:e0286889.
    PubMed     Abstract available

  71. WANG S, Wang Y, Zhuang J, Wu Y, et al
    Prognostic significance of index (LANR) composed of preoperative lymphocytes, albumin, and neutrophils in patients with stage IB-IIA cervical cancer.
    PLoS One. 2023;18:e0290905.
    PubMed     Abstract available

  72. MANTULA F, Toefy Y
    Women and health providers' perspectives on male support for cervical cancer screening in Gwanda district, Zimbabwe.
    PLoS One. 2023;18:e0282931.
    PubMed     Abstract available

  73. IORDANISHVILI S, Metreveli T, Lipartia E, Gachechiladze K, et al
    The HPV-TP53-MALAT1 Axis: Unravelling interactions in cervical cancer development.
    PLoS One. 2023;18:e0291725.
    PubMed     Abstract available

  74. FERREIRA HNC, Capistrano GN, Morais TNB, Costa KTDS, et al
    Screening and hospitalization of breast and cervical cancer in Brazil from 2010 to 2022: A time-series study.
    PLoS One. 2023;18:e0278011.
    PubMed     Abstract available

  75. QAQISH A, Abdo N, Abbas MM, Saadeh N, et al
    Awareness and knowledge of physicians and residents on the non-sexual routes of human papilloma virus (HPV) infection and their perspectives on anti-HPV vaccination in Jordan.
    PLoS One. 2023;18:e0291643.
    PubMed     Abstract available

  76. ZHAO X, Gopalappa C
    Joint modeling HIV and HPV using a new hybrid agent-based network and compartmental simulation technique.
    PLoS One. 2023;18:e0288141.
    PubMed     Abstract available

  77. DESTA M, Getaneh T, Yeserah B, Worku Y, et al
    Correction: Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0294799.
    PubMed     Abstract available

  78. TACHIWENYIKA E, Dhodho M, Muchedzi A, Sibanda TP, et al
    Prevalence of Cervical Cancer and Clinical Management of Women Screened positive using visual inspection with acetic acid and Cervicography in selected public sector health facilities of Manicaland and Midlands provinces of Zimbabwe, 2021.
    PLoS One. 2023;18:e0294115.
    PubMed     Abstract available

  79. MAHUMUD RA, Alam K, Dunn J, Gow J, et al
    Correction: The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
    PLoS One. 2023;18:e0295688.
    PubMed     Abstract available

  80. QULU W, Mtshali A, Osman F, Ndlela N, et al
    High-risk human papillomavirus prevalence among South African women diagnosed with other STIs and BV.
    PLoS One. 2023;18:e0294698.
    PubMed     Abstract available

  81. ALMASOUDI HH, Nahari MH, Alhazmi AYM, Almasabi SHA, et al
    Delineating Pixantrone Maleate's adroit activity against cervical cancer proteins through multitargeted docking-based MM\GBSA, QM-DFT and MD simulation.
    PLoS One. 2023;18:e0295714.
    PubMed     Abstract available

  82. RAZZAK MA, Islam MN, Aadeeb MS, Tasnim T, et al
    Digital health interventions for cervical cancer care: A systematic review and future research opportunities.
    PLoS One. 2023;18:e0296015.
    PubMed     Abstract available

  83. AL-OSEELY S, Abdul Manaf R, Ismail S
    Factors affecting cervical cancer screening among Yemeni immigrant women in Klang Valley, Malaysia: A cross sectional study.
    PLoS One. 2023;18:e0290152.
    PubMed     Abstract available

  84. GEBREMESKEL TG, Gebretatios MZ
    Determinants of cervical cancer screening utilization among HIV-positive women, in public general hospitals of Central Zone, Tigray, Ethiopia, 2020: Case-control study.
    PLoS One. 2023;18:e0289042.
    PubMed     Abstract available

  85. NOVAIS IR, Coelho CO, Machado HC, Surita F, et al
    Cervical cancer screening in Brazilian Amazon Indigenous women: Towards the intensification of public policies for prevention.
    PLoS One. 2023;18:e0294956.
    PubMed     Abstract available

  86. TOSADO-RODRIGUEZ E, Mendez LB, Espino AM, Dorta-Estremera S, et al
    Inflammatory cytokines and a diverse cervicovaginal microbiota associate with cervical dysplasia in a cohort of Hispanics living in Puerto Rico.
    PLoS One. 2023;18:e0284673.
    PubMed     Abstract available

    January 2022
  87. DEMISSIE BW, Azeze GA, Asseffa NA, Lake EA, et al
    Communities' perceptions towards cervical cancer and its screening in Wolaita zone, southern Ethiopia: A qualitative study.
    PLoS One. 2022;17:e0262142.
    PubMed     Abstract available

  88. BRUGGMANN D, Quinkert-Schmolke K, Jaque JM, Quarcoo D, et al
    Global cervical cancer research: A scientometric density equalizing mapping and socioeconomic analysis.
    PLoS One. 2022;17:e0261503.
    PubMed     Abstract available

  89. LIA M, Horn LC, Sodeikat P, Hockel M, et al
    The diagnostic value of core needle biopsy in cervical cancer: A retrospective analysis.
    PLoS One. 2022;17:e0262257.
    PubMed     Abstract available

  90. GONZALEZ A, Sanchez R, Camargo M, Soto-De Leon SC, et al
    Cervical cancer screening programme attendance and compliance predictors regarding Colombia's Amazon region.
    PLoS One. 2022;17:e0262069.
    PubMed     Abstract available

  91. BULA AK, Lee F, Chapola J, Mapanje C, et al
    Perceptions of cervical cancer and motivation for screening among women in Rural Lilongwe, Malawi: A qualitative study.
    PLoS One. 2022;17:e0262590.
    PubMed     Abstract available

  92. KORN AK, Muzingwani L, O'Bryan G, Ensminger A, et al
    Cervical cancer screening and treatment, HIV infection, and age: Program implementation in seven regions of Namibia.
    PLoS One. 2022;17:e0263920.
    PubMed     Abstract available

  93. SEIFU B, Fikru C, Yilma D, Tessema F, et al
    Predictors of time to death among cervical cancer patients at Tikur Anbesa specialized hospital from 2014 to 2019: A survival analysis.
    PLoS One. 2022;17:e0264369.
    PubMed     Abstract available

  94. LEWIS S, Mphande M, Chibwana F, Gumbo T, et al
    Association of HIV status and treatment characteristics with VIA screening outcomes in Malawi: A retrospective analysis.
    PLoS One. 2022;17:e0262904.
    PubMed     Abstract available

  95. MIYAJI KT, Infante V, Picone CM, Levi JE, et al
    Human Papillomavirus (HPV) seroprevalence, cervical HPV prevalence, genotype distribution and cytological lesions in solid organ transplant recipients and immunocompetent women in Sao Paulo, Brazil.
    PLoS One. 2022;17:e0262724.
    PubMed     Abstract available

  96. OMENAI SA, Ajani MA, Okolo CA
    Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.
    PLoS One. 2022;17:e0263615.
    PubMed     Abstract available

  97. SALARIA D, Rolta R, Mehta J, Awofisayo O, et al
    Phytoconstituents of traditional Himalayan Herbs as potential inhibitors of Human Papillomavirus (HPV-18) for cervical cancer treatment: An In silico Approach.
    PLoS One. 2022;17:e0265420.
    PubMed     Abstract available

  98. CHAW L, Lee SHF, Ja'afar NIH, Lim E, et al
    Reasons for non-attendance to cervical cancer screening and acceptability of HPV self-sampling among Bruneian women: A cross-sectional study.
    PLoS One. 2022;17:e0262213.
    PubMed     Abstract available

  99. ZENG J, Sun P, Ping Q, Jiang S, et al
    Clinical outcome of FIGO 2018 stage IB3/IIA2 cervical cancer treated by neoadjuvant chemotherapy followed by radical surgery due to lack of radiotherapy equipment: A retrospective comparison with concurrent chemoradiotherapy.
    PLoS One. 2022;17:e0266001.
    PubMed     Abstract available

  100. PHAIPHICHIT J, Paboriboune P, Kunnavong S, Chanthavilay P, et al
    Factors associated with cervical cancer screening among women aged 25-60 years in Lao People's Democratic Republic.
    PLoS One. 2022;17:e0266592.
    PubMed     Abstract available

  101. SAKAMOTO J, Saito M, Zhang S, Takakura M, et al
    Determination of human papillomavirus type in archival tissue specimens of invasive cervical cancer using molecular mapping and E6/E7-based polymerase chain reaction.
    PLoS One. 2022;17:e0265996.
    PubMed     Abstract available

  102. D S P, Chaturvedi PK, Krishnamoorthy D, Seo YS, et al
    Fused toes homolog, a potential molecular regulator of human papillomavirus type 16 E6 and E7 oncoproteins in cervical cancer.
    PLoS One. 2022;17:e0266532.
    PubMed     Abstract available

  103. YACOUTI A, Elkhoudri N, El Got A, Benider A, et al
    Awareness, attitudes and acceptability of the HPV vaccine among female university students in Morocco.
    PLoS One. 2022;17:e0266081.
    PubMed     Abstract available

  104. ROJAS ROJAS T, Poizot-Martin I, Rey D, Duvivier C, et al
    Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.
    PLoS One. 2022;17:e0261069.
    PubMed     Abstract available

  105. DENG ZM, Chen GH, Dai FF, Liu SY, et al
    The clinical value of miRNA-21 in cervical cancer: A comprehensive investigation based on microarray datasets.
    PLoS One. 2022;17:e0267108.
    PubMed     Abstract available

  106. TEKALIGN T, Teshome M
    Prevalence and determinants of late-stage presentation among cervical cancer patients, a systematic review and meta-analysis.
    PLoS One. 2022;17:e0267571.
    PubMed     Abstract available

  107. ELIES A, Bonneau C, Houzard S, Rouzier R, et al
    Impact of catch-up human papillomavirus vaccination on cervical conization rate in a real-life population in France.
    PLoS One. 2022;17:e0264821.
    PubMed     Abstract available

  108. MBULAWA ZZA, Phohlo K, Garcia-Jardon M, Williamson AL, et al
    High human papillomavirus (HPV)-35 prevalence among South African women with cervical intraepithelial neoplasia warrants attention.
    PLoS One. 2022;17:e0264498.
    PubMed     Abstract available

  109. TAYLOR MM, Wi T, Gerbase A, Thwin SS, et al
    Assessment of country implementation of the WHO global health sector strategy on sexually transmitted infections (2016-2021).
    PLoS One. 2022;17:e0263550.
    PubMed     Abstract available

  110. DUFEIL E, Kenfack B, Tincho E, Fouogue J, et al
    Addition of digital VIA/VILI to conventional naked-eye examination for triage of HPV-positive women: A study conducted in a low-resource setting.
    PLoS One. 2022;17:e0268015.
    PubMed     Abstract available

  111. WINARTO H, Habiburrahman M, Dorothea M, Wijaya A, et al
    Knowledge, attitudes, and practices among Indonesian urban communities regarding HPV infection, cervical cancer, and HPV vaccination.
    PLoS One. 2022;17:e0266139.
    PubMed     Abstract available

  112. CHANGKUN Z, Bishwajit G, Ji L, Tang S, et al
    Sociodemographic correlates of cervix, breast and oral cancer screening among Indian women.
    PLoS One. 2022;17:e0265881.
    PubMed     Abstract available

  113. NIE C, Qin H, Zhang L
    Identification and validation of a prognostic signature related to hypoxic tumor microenvironment in cervical cancer.
    PLoS One. 2022;17:e0269462.
    PubMed     Abstract available

  114. AMO-ANTWI K, Agambire R, Konney TO, Nguah SB, et al
    Health-related quality of life among cervical cancer survivors at a tertiary hospital in Ghana.
    PLoS One. 2022;17:e0268831.
    PubMed     Abstract available

  115. MEBRATIE AE, Moges NA, Meselu BT, Melesse MF, et al
    Time to death from cervical cancer and predictors among cervical cancer patients in Felege Hiwot Comprehensive Specialized Hospital, North West Ethiopia: Facility-based retrospective follow-up study.
    PLoS One. 2022;17:e0269576.
    PubMed     Abstract available

  116. SRIPAN P, Pongnikorn D, Chitapanarux I, Tangmunkongvorakul A, et al
    Geographical risk pattern and temporal trends in incidence of HPV-related cancers in northern Thailand: A population-based study.
    PLoS One. 2022;17:e0270670.
    PubMed     Abstract available

  117. LEMMA D, Aboma M, Girma T, Dechesa A, et al
    Determinants of utilization of cervical cancer screening among women in the age group of 30-49 years in Ambo Town, Central Ethiopia: A case-control study.
    PLoS One. 2022;17:e0270821.
    PubMed     Abstract available

  118. EL MANSOURI N, Ferrera L, Kharbach A, Achbani A, et al
    Awareness and knowledge associated to Human papillomavirus infection among university students in Morocco: A cross-sectional study.
    PLoS One. 2022;17:e0271222.
    PubMed     Abstract available

  119. KIM M, Kim J, Park NJ, Park JY, et al
    Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping.
    PLoS One. 2022;17:e0267836.
    PubMed     Abstract available

  120. BARRERA FERRO D, Bayer S, Bocanegra L, Brailsford S, et al
    Understanding no-show behaviour for cervical cancer screening appointments among hard-to-reach women in Bogota, Colombia: A mixed-methods approach.
    PLoS One. 2022;17:e0271874.
    PubMed     Abstract available

  121. AYANTO SY, Belachew T, Wordofa MA
    Effectiveness of couple education and counseling on knowledge, attitude and uptake of cervical cancer screening service among women of child bearing age in Southern Ethiopia: A cluster randomized trial protocol.
    PLoS One. 2022;17:e0270663.
    PubMed     Abstract available

  122. YANG Z, Liu J, Wang Q
    Diagnose earlier, live longer? The impact of cervical and breast cancer screening on life span.
    PLoS One. 2022;17:e0270347.
    PubMed     Abstract available

  123. SHIMELS T, Gashaw B, Gedif T
    Association between delayed initiation of treatment indications and survival in patients with cervical cancer: A systematic review and meta-analysis protocol.
    PLoS One. 2022;17:e0271604.
    PubMed     Abstract available

  124. BEYEN MW, Bulto GA, Chaka EE, Debelo BT, et al
    Human papillomavirus vaccination uptake and its associated factors among adolescent school girls in Ambo town, Oromia region, Ethiopia, 2020.
    PLoS One. 2022;17:e0271237.
    PubMed     Abstract available

  125. GEBRIE A
    Disease progression role as well as the diagnostic and prognostic value of microRNA-21 in patients with cervical cancer: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0268480.
    PubMed     Abstract available

  126. LIU SS, Chan KKL, Wei TN, Tse KY, et al
    Clinical performance of the Roche Cobas 4800 HPV test for primary cervical cancer screening in a Chinese population.
    PLoS One. 2022;17:e0272721.
    PubMed     Abstract available

  127. FRIEBEL-KLINGNER TM, Iyer HS, Ramogola-Masire D, Bazzett-Matabele L, et al
    Evaluating the geographic distribution of cervical cancer patients presenting to a multidisciplinary gynecologic oncology clinic in Gaborone, Botswana.
    PLoS One. 2022;17:e0271679.
    PubMed     Abstract available

  128. CORREA RM, Baena A, Valls J, Colucci MC, et al
    Distribution of human papillomavirus genotypes by severity of cervical lesions in HPV screened positive women from the ESTAMPA study in Latin America.
    PLoS One. 2022;17:e0272205.
    PubMed     Abstract available

  129. YANG Z, Zhang Y, Stubbe-Espejel A, Zhao Y, et al
    Vaginal microbiota and personal risk factors associated with HPV status conversion-A new approach to reduce the risk of cervical cancer?
    PLoS One. 2022;17:e0270521.
    PubMed     Abstract available

  130. JO A, Joh HM, Bae JH, Kim SJ, et al
    Plasma activated medium prepared by a bipolar microsecond-pulsed atmospheric pressure plasma jet array induces mitochondria-mediated apoptosis in human cervical cancer cells.
    PLoS One. 2022;17:e0272805.
    PubMed     Abstract available

  131. ROMLI R, Abd Rahman R, Chew KT, Mohd Hashim S, et al
    Empirical investigation of e-health intervention in cervical cancer screening: A systematic literature review.
    PLoS One. 2022;17:e0273375.
    PubMed     Abstract available

  132. YOSHIKAWA N, Yoshihara M, Tamauchi S, Ikeda Y, et al
    Hypoalbuminemia for the prediction of survival in patients with stage IVB cervical cancer.
    PLoS One. 2022;17:e0273876.
    PubMed     Abstract available

  133. HOMBAIAH C, Madhu B, Gopi A, Narayana Murthy MR, et al
    Effects of mobile Health (mHealth) application on cervical cancer prevention knowledge and screening among women social support groups with low-socioeconomic status in Mysuru city, Southern India.
    PLoS One. 2022;17:e0273070.
    PubMed     Abstract available

  134. LUBEYA MK, Mwanahamuntu M, Chibwesha C, Mukosha M, et al
    Implementation strategies to increase human papillomavirus vaccination uptake for adolescent girls in sub-Saharan Africa: A scoping review protocol.
    PLoS One. 2022;17:e0267617.
    PubMed     Abstract available

  135. STERNJAKOB-MARTHALER A, Berko-Gottel B, Rissland J, Schope J, et al
    Human papillomavirus vaccination of girls in the German model region Saarland: Insurance data-based analysis and identification of starting points for improving vaccination rates.
    PLoS One. 2022;17:e0273332.
    PubMed     Abstract available

  136. BUTLER TL, Lee N, Anderson K, Brotherton JML, et al
    Under-screened Aboriginal and Torres Strait Islander women's perspectives on cervical screening.
    PLoS One. 2022;17:e0271658.
    PubMed     Abstract available

  137. GALESHI M, Shirafkan H, Yazdani S, Motaghi Z, et al
    Reproductive health needs of Human papillomavirus (HPV) positive women: A systematic review.
    PLoS One. 2022;17:e0266819.
    PubMed     Abstract available

  138. DERBIE A, Amare B, Misgan E, Nibret E, et al
    Histopathological profile of cervical punch biopsies and risk factors associated with high-grade cervical precancerous lesions and cancer in northwest Ethiopia.
    PLoS One. 2022;17:e0274466.
    PubMed     Abstract available

  139. MASEKO B, Bula A, Sasse S, Thom A, et al
    Opinions on integrating couple counselling and female sexual reproductive health services into Voluntary Medical Male Circumcision services in Lilongwe, Malawi.
    PLoS One. 2022;17:e0273627.
    PubMed     Abstract available

  140. KALIFF M, Lillsunde Larsson G, Helenius G, Karlsson MG, et al
    Full genotyping and FAM19A4/miR124-2 methylation analysis in high-risk human papillomavirus-positive samples from women over 30 years participating in cervical cancer screening in Orebro, Sweden.
    PLoS One. 2022;17:e0274825.
    PubMed     Abstract available

  141. ZIBAKO P, Tsikai N, Manyame S, Ginindza TG, et al
    Cervical cancer management in Zimbabwe (2019-2020).
    PLoS One. 2022;17:e0274884.
    PubMed     Abstract available

  142. DAI L, Mugaanyi J, Zhang T, Tong J, et al
    A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas.
    PLoS One. 2022;17:e0274823.
    PubMed     Abstract available

  143. ABAS BI, Demirbolat GM, Cevik O
    Wharton jelly-derived mesenchymal stem cell exosomes induce apoptosis and suppress EMT signaling in cervical cancer cells as an effective drug carrier system of paclitaxel.
    PLoS One. 2022;17:e0274607.
    PubMed     Abstract available

    Individual and intimate-partner factors associated with cervical cancer screening in Central Uganda.
    PLoS One. 2022;17:e0274602.
    PubMed     Abstract available

  145. ZENO EE, Brewer NT, Spees LP, Des Marais AC, et al
    Racial and ethnic differences in cervical cancer screening barriers and intentions: The My Body My Test-3 HPV self-collection trial among under-screened, low-income women.
    PLoS One. 2022;17:e0274974.
    PubMed     Abstract available

  146. BRONK JK, Kapadia C, Wu X, Chapman BV, et al
    Feasibility of a novel non-invasive swab technique for serial whole-exome sequencing of cervical tumors during chemoradiation therapy.
    PLoS One. 2022;17:e0274457.
    PubMed     Abstract available

  147. SIM JH, Jang DM, Cho HS, Park JY, et al
    Association of red cell distribution width/albumin ratio with intraoperative blood transfusion in cervical cancer patients.
    PLoS One. 2022;17:e0277481.
    PubMed     Abstract available

  148. BASILETTI JA, Valls J, Poklepovich T, Fellner MD, et al
    Human papillomavirus genotyping using next generation sequencing (NGS) in cervical lesions: Genotypes by histologic grade and their relative proportion in multiple infections.
    PLoS One. 2022;17:e0278117.
    PubMed     Abstract available

  149. AL-SHIBLI K, Mohammed HAL, Maurseth R, Fostervold M, et al
    Impact of HPV mRNA types 16, 18, 45 detection on the risk of CIN3+ in young women with normal cervical cytology.
    PLoS One. 2022;17:e0275858.
    PubMed     Abstract available

  150. PETERSON CE, Dykens JA, Weine SM, Holt HK, et al
    Assessing the interrelationship between stigma, social influence, and cervical cancer prevention in an urban underserved setting: An exploratory study.
    PLoS One. 2022;17:e0278538.
    PubMed     Abstract available

  151. DES MARAIS AC, Brewer NT, Knight S, Smith JS, et al
    Patient perspectives on cervical cancer screening interventions among underscreened women.
    PLoS One. 2022;17:e0277791.
    PubMed     Abstract available

  152. DENNINGHOFF V, von Petery F, Fresno C, Galarza M, et al
    Clinical implementation of a cervical cancer screening program via co-testing at a university hospital.
    PLoS One. 2022;17:e0278476.
    PubMed     Abstract available

  153. MALKIN J, Allen Scott L, Alberga Machado A, Teare G, et al
    Factors influencing human papillomavirus school-based immunization in Alberta: A mixed-methods study protocol.
    PLoS One. 2022;17:e0278472.
    PubMed     Abstract available

  154. HASHEMI L, Ormsbee ME, Patel PJ, Nielson JA, et al
    A Drosophila model of HPV16-induced cancer reveals conserved disease mechanism.
    PLoS One. 2022;17:e0278058.
    PubMed     Abstract available

  155. KHOO SP, Muhammad Ridzuan Tan NA, Rajasuriar R, Nasir NH, et al
    Changes in genital Human Papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program.
    PLoS One. 2022;17:e0278477.
    PubMed     Abstract available

  156. AMADO G, Weldegebreal F, Birhanu S, Dessie Y, et al
    Cervical cancer screening practices and its associated factors among females of reproductive age in Durame town, Southern Ethiopia.
    PLoS One. 2022;17:e0279870.
    PubMed     Abstract available

    January 2021
  157. CHISALE MABOTJA M, Levin J, Kawonga M
    Beliefs and perceptions regarding cervical cancer and screening associated with Pap smear uptake in Johannesburg: A cross-sectional study.
    PLoS One. 2021;16:e0246574.
    PubMed     Abstract available

  158. MANYAU PMC, Mabeka M, Mudzviti T, Kadzatsa W, et al
    Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department.
    PLoS One. 2021;16:e0245383.
    PubMed     Abstract available

  159. DEVINE A, Vahanian A, Sawadogo B, Zan S, et al
    Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study.
    PLoS One. 2021;16:e0248832.
    PubMed     Abstract available

  160. BOGALE AL, Teklehaymanot T, Haidar Ali J, Kassie GM, et al
    Knowledge, attitude and practice of cervical cancer screening among women infected with HIV in Africa: Systematic review and meta-analysis.
    PLoS One. 2021;16:e0249960.
    PubMed     Abstract available

  161. NGCAMPHALALA C, Ostensson E, Ginindza TG
    The economic burden of cervical cancer in Eswatini: Societal perspective.
    PLoS One. 2021;16:e0250113.
    PubMed     Abstract available

  162. JUBAIR L, Lam AK, Fallaha S, McMillan NAJ, et al
    CRISPR/Cas9-loaded stealth liposomes effectively cleared established HPV16-driven tumours in syngeneic mice.
    PLoS One. 2021;16:e0223288.
    PubMed     Abstract available

  163. PENG L, Hayatullah G, Zhou H, Chang S, et al
    Tumor microenvironment characterization in cervical cancer identifies prognostic relevant gene signatures.
    PLoS One. 2021;16:e0249374.
    PubMed     Abstract available

  164. VIEIRA MA, de Araujo RLC, da Cunha Andrade CEM, Schmidt RL, et al
    A randomized clinical trial of a new anti-cervical stenosis device after conization by loop electrosurgical excision.
    PLoS One. 2021;16:e0242067.
    PubMed     Abstract available

  165. SONGANE M, Grossmann V
    The patent buyout price for human papilloma virus (HPV) vaccine and the ratio of R&D costs to the patent value.
    PLoS One. 2021;16:e0244722.
    PubMed     Abstract available

  166. VALE DB, Silva MT, Discacciati MG, Polegatto I, et al
    Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country.
    PLoS One. 2021;16:e0251688.
    PubMed     Abstract available

  167. SUZUKI S, Hayata E, Hoshi SI, Sekizawa A, et al
    Current status of cervical cytology during pregnancy in Japan.
    PLoS One. 2021;16:e0245282.
    PubMed     Abstract available

  168. BADRE-ESFAHANI S, Petersen LK, Tatari CR, Blaakaer J, et al
    Perceptions of cervical cancer prevention among a group of ethnic minority women in Denmark-A qualitative study.
    PLoS One. 2021;16:e0250816.
    PubMed     Abstract available

  169. LIM YJ, Lee HN
    Optimal use of radiotherapy in the definitive treatment of non-bulky IB-IIA cervical cancer: A population-based long-term survival analysis.
    PLoS One. 2021;16:e0253649.
    PubMed     Abstract available

  170. KARAWEKPANYAWONG N, Kaewkitikul K, Maneeton B, Maneeton N, et al
    The prevalence of depressive disorder and its association in Thai cervical cancer patients.
    PLoS One. 2021;16:e0252779.
    PubMed     Abstract available

  171. LI Y, Kong Q, Wei H, Wang Y, et al
    Comparison of the complications between minimally invasive surgery and open surgical treatments for early-stage cervical cancer: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0253143.
    PubMed     Abstract available

  172. MOISE RK, Balise R, Ragin C, Kobetz E, et al
    Cervical cancer risk and access: Utilizing three statistical tools to assess Haitian women in South Florida.
    PLoS One. 2021;16:e0254089.
    PubMed     Abstract available

  173. BEYENE T, Akibu M, Bekele H, Seyoum W, et al
    Risk factors for precancerous cervical lesion among women screened for cervical cancer in south Ethiopia: Unmatched case-control study.
    PLoS One. 2021;16:e0254663.
    PubMed     Abstract available

  174. HOPKINS KL, Jaffer M, Hlongwane KE, Otwombe K, et al
    Assessing national cervical cancer screening guidelines: Results from an HIV testing clinic also screening for cervical cancer and HPV in Soweto, South Africa.
    PLoS One. 2021;16:e0255124.
    PubMed     Abstract available

  175. TERMRUNGRUANGLERT W, Khemapech N, Vasuratna A, Havanond P, et al
    The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand.
    PLoS One. 2021;16:e0245894.
    PubMed     Abstract available

  176. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available

  177. KEETILE M, Ndlovu K, Letamo G, Disang M, et al
    Factors associated with and socioeconomic inequalities in breast and cervical cancer screening among women aged 15-64 years in Botswana.
    PLoS One. 2021;16:e0255581.
    PubMed     Abstract available

  178. ST-MARTIN G, Viborg PH, Andersen ABT, Andersen B, et al
    Histological outcomes in HPV-screened elderly women in Denmark.
    PLoS One. 2021;16:e0246902.
    PubMed     Abstract available

  179. PONCET L, Panjo H, Ringa V, Andro A, et al
    Do vulnerable groups access prevention services? Cervical cancer screening and HIV testing among homeless migrant women in the Paris metropolitan area.
    PLoS One. 2021;16:e0255900.
    PubMed     Abstract available

  180. SUCHONSKA B, Gajzlerska-Majewska W, Wielgos M
    Evaluation of a real-time optoelectronic method in the diagnostics of CIN over four years of observations.
    PLoS One. 2021;16:e0247702.
    PubMed     Abstract available

  181. SUNDSTROM K, Lamin H, Dillner J
    Validation of the cobas 6800 human papillomavirus test in primary cervical screening.
    PLoS One. 2021;16:e0247291.
    PubMed     Abstract available

  182. ITKIN B, Garcia A, Straminsky S, Adelchanow ED, et al
    Prevalence of HER2 overexpression and amplification in cervical cancer: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0257976.
    PubMed     Abstract available

  183. KUGUYO O, Dube Mandishora RS, Thomford NE, Makunike-Mutasa R, et al
    High-risk HPV genotypes in Zimbabwean women with cervical cancer: Comparative analyses between HIV-negative and HIV-positive women.
    PLoS One. 2021;16:e0257324.
    PubMed     Abstract available

  184. SHIN HY, Song SY, Jun JK, Kim KY, et al
    Barriers and strategies for cervical cancer screening: What do female university students know and want?
    PLoS One. 2021;16:e0257529.
    PubMed     Abstract available

  185. TEMESGEN MM, Alemu T, Shiferaw B, Legesse S, et al
    Prevalence of oncogenic human papillomavirus (HPV 16/18) infection, cervical lesions and its associated factors among women aged 21-49 years in Amhara region, Northern Ethiopia.
    PLoS One. 2021;16:e0248949.
    PubMed     Abstract available

  186. TORRES KL, Rondon HHMF, Martins TR, Martins S, et al
    Moving towards a strategy to accelerate cervical cancer elimination in a high-burden city-Lessons learned from the Amazon city of Manaus, Brazil.
    PLoS One. 2021;16:e0258539.
    PubMed     Abstract available

  187. ZUBERI Z, Mremi A, Chilongola JO, Semango G, et al
    Expression analysis of p16 and TOP2A protein biomarkers in cervical cancer lesions and their correlation with clinico-histopathological characteristics in a referral hospital, Tanzania.
    PLoS One. 2021;16:e0259096.
    PubMed     Abstract available

  188. DESTA M, Getaneh T, Yeserah B, Worku Y, et al
    Cervical cancer screening utilization and predictors among eligible women in Ethiopia: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0259339.
    PubMed     Abstract available

  189. GUI T, Chen Z, Chen F
    Validation of the indication for colposcopy proposed by the 2019 ASCCP risk-based management consensus guidelines: A single-center study in China.
    PLoS One. 2021;16:e0253493.
    PubMed     Abstract available

  190. WOROMOGO SH, Ambounda Ledaga N, Yagata-Moussa FE, Mihindou AS, et al
    Uterine cervical neoplasms mass screening at the University Hospital Centre of Libreville, Gabon: Associated factors with precancerous and cancerous lesions.
    PLoS One. 2021;16:e0255289.
    PubMed     Abstract available

  191. JU X, Canfell K, Howard K, Garvey G, et al
    Population-based utility scores for HPV infection and cervical squamous cell carcinoma among Australian Indigenous women.
    PLoS One. 2021;16:e0254575.
    PubMed     Abstract available

  192. HERNANDEZ-LOPEZ R, Hermosillo L, Leon-Maldonado L, Velazquez-Cruz R, et al
    Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women.
    PLoS One. 2021;16:e0254946.
    PubMed     Abstract available

  193. HARTMAN CA, Braganca JF, Gurgel MSC, Zeferino LC, et al
    Conservative treatment of microinvasive squamous cell carcinoma of the cervix stage IA1: Defining conization height to an optimal oncological outcome.
    PLoS One. 2021;16:e0253998.
    PubMed     Abstract available

  194. TANAKA LF, Schriefer D, Radde K, Schauberger G, et al
    Impact of opportunistic screening on squamous cell and adenocarcinoma of the cervix in Germany: A population-based case-control study.
    PLoS One. 2021;16:e0253801.
    PubMed     Abstract available

  195. DA-ANO R, Lucia F, Masson I, Abgral R, et al
    A transfer learning approach to facilitate ComBat-based harmonization of multicentre radiomic features in new datasets.
    PLoS One. 2021;16:e0253653.
    PubMed     Abstract available

  196. ALISSA NA
    Knowledge and intentions regarding the Pap smear test among Saudi Arabian women.
    PLoS One. 2021;16:e0253850.
    PubMed     Abstract available

  197. MAGKANA M, Mentzelopoulou P, Magkana E, Pampanos A, et al
    The p16/ki-67 assay is a safe, effective and rapid approach to triage women with mild cervical lesions.
    PLoS One. 2021;16:e0253045.
    PubMed     Abstract available

  198. ABBASIFARID E, Bolhassani A, Irani S, Sotoodehnejadnematalahi F, et al
    Synergistic effects of exosomal crocin or curcumin compounds and HPV L1-E7 polypeptide vaccine construct on tumor eradication in C57BL/6 mouse model.
    PLoS One. 2021;16:e0258599.
    PubMed     Abstract available

  199. NAJIOULLAH F, Dorival MJ, Joachim C, Dispagne C, et al
    Genotype distribution of cervical HPV among Caribbean women in a population-based study in Martinique: The DEPIPAPUFR study.
    PLoS One. 2021;16:e0257915.
    PubMed     Abstract available

  200. SHIBATA T, Nakagawa M, Coleman HN, Owens SM, et al
    Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota.
    PLoS One. 2021;16:e0237556.
    PubMed     Abstract available

  201. SINGINI MG, Sitas F, Bradshaw D, Chen WC, et al
    Ranking lifestyle risk factors for cervical cancer among Black women: A case-control study from Johannesburg, South Africa.
    PLoS One. 2021;16:e0260319.
    PubMed     Abstract available

  202. HARIMA Y, Ariga T, Kaneyasu Y, Ikushima H, et al
    Clinical value of serum biomarkers, squamous cell carcinoma antigen and apolipoprotein C-II in follow-up of patients with locally advanced cervical squamous cell carcinoma treated with radiation: A multicenter prospective cohort study.
    PLoS One. 2021;16:e0259235.
    PubMed     Abstract available

  203. MOSTAID MS, Mumu SB, Haque MA, Sharmin S, et al
    Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women.
    PLoS One. 2021;16:e0261984.
    PubMed     Abstract available

  204. SIEGEL EM, Ajidahun A, Berglund A, Guerrero W, et al
    Genome-wide host methylation profiling of anal and cervical carcinoma.
    PLoS One. 2021;16:e0260857.
    PubMed     Abstract available

  205. BAEDYANANDA F, Chaiwongkot A, Varadarajan S, Bhattarakosol P, et al
    HPV16 E1 dysregulated cellular genes involved in cell proliferation and host DNA damage: A possible role in cervical carcinogenesis.
    PLoS One. 2021;16:e0260841.
    PubMed     Abstract available

  206. BALEYDIER I, Vassilakos P, Vinals R, Wisniak A, et al
    Study protocol for a two-site clinical trial to validate a smartphone-based artificial intelligence classifier identifying cervical precancer and cancer in HPV-positive women in Cameroon.
    PLoS One. 2021;16:e0260776.
    PubMed     Abstract available

  207. HUSAIYIN S, Jiao Z, Yimamu K, Maisaidi R, et al
    ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients.
    PLoS One. 2021;16:e0260915.
    PubMed     Abstract available

  208. ISSA T, Babi A, Issanov A, Akilzhanova A, et al
    Knowledge and awareness of human papillomavirus infection and human papillomavirus vaccine among Kazakhstani women attending gynecological clinics.
    PLoS One. 2021;16:e0261203.
    PubMed     Abstract available

    January 2020
  209. FOGELBERG S, Clements MS, Pedersen K, Sy S, et al
    Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden.
    PLoS One. 2020;15:e0239611.
    PubMed     Abstract available

  210. KHAN MA, Tiwari D, Dongre A, Sadaf, et al
    Exploring the p53 connection of cervical cancer pathogenesis involving north-east Indian patients.
    PLoS One. 2020;15:e0238500.
    PubMed     Abstract available

  211. GUO A, Drake BF, Khan YM, Langabeer Ii JR, et al
    Time-series cardiovascular risk factors and receipt of screening for breast, cervical, and colon cancer: The Guideline Advantage.
    PLoS One. 2020;15:e0236836.
    PubMed     Abstract available

  212. ABU SH, Woldehanna BT, Nida ET, Tilahun AW, et al
    The role of health education on cervical cancer screening uptake at selected health centers in Addis Ababa.
    PLoS One. 2020;15:e0239580.
    PubMed     Abstract available

  213. MOODLEY J, Constant D, Mwaka AD, Scott SE, et al
    Mapping awareness of breast and cervical cancer risk factors, symptoms and lay beliefs in Uganda and South Africa.
    PLoS One. 2020;15:e0240788.
    PubMed     Abstract available

  214. SHRESTHA G, Mulmi R, Phuyal P, Thakur RK, et al
    Experiences of cervical cancer survivors in Chitwan, Nepal: A qualitative study.
    PLoS One. 2020;15:e0234834.
    PubMed     Abstract available

  215. WOLLANCHO W, Amdissa D, Bamboro S, Wasihun Y, et al
    Determining behavioral intention and its predictors towards cervical cancer screening among women in Gomma district, Jimma, Ethiopia: Application of the theory of planned behavior.
    PLoS One. 2020;15:e0238472.
    PubMed     Abstract available

  216. Correction: Long-term protection of HPV test in women at risk of cervical cancer.
    PLoS One. 2020;15:e0243000.
    PubMed     Abstract available

  217. ISABIRYE A, Mbonye MK, Kwagala B
    Predictors of cervical cancer screening uptake in two districts of Central Uganda.
    PLoS One. 2020;15:e0243281.
    PubMed     Abstract available

  218. MEGERSA BS, Bussmann H, Barnighausen T, Muche AA, et al
    Community cervical cancer screening: Barriers to successful home-based HPV self-sampling in Dabat district, North Gondar, Ethiopia. A qualitative study.
    PLoS One. 2020;15:e0243036.
    PubMed     Abstract available

  219. KASSIE AM, Abate BB, Kassaw MW, Aragie TG, et al
    Impact of knowledge and attitude on the utilization rate of cervical cancer screening tests among Ethiopian women: A systematic review and meta-analysis.
    PLoS One. 2020;15:e0239927.
    PubMed     Abstract available

  220. KATO M, Onoyama I, Kawakami M, Yoshida S, et al
    Downregulation of 5-hydroxymethylcytosine is associated with the progression of cervical intraepithelial neoplasia.
    PLoS One. 2020;15:e0241482.
    PubMed     Abstract available

  221. TOUNKARA FK, Teguete I, Guedou FA, Goma-Matsetse E, et al
    Human papillomavirus genotype distribution and factors associated among female sex workers in West Africa.
    PLoS One. 2020;15:e0242711.
    PubMed     Abstract available

  222. TAKU O, Meiring TL, Gustavsson I, Phohlo K, et al
    Acceptability of self- collection for human papillomavirus detection in the Eastern Cape, South Africa.
    PLoS One. 2020;15:e0241781.
    PubMed     Abstract available

  223. TOYODA Y, Tabuchi T, Hama H, Morishima T, et al
    Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix.
    PLoS One. 2020;15:e0244644.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Cervical Cancer is free of charge.